Rockwell Medical (RMTI) Soars: Stock Adds 9.7% in Session
Rockwell Medical, Inc. RMTI was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company, as the stock is now down 11.3% in the past one-month time frame.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Rockwell Medical. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Rockwell Medical currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Rockwell Medical, Inc. Price
Rockwell Medical, Inc. price | Rockwell Medical, Inc. Quote
A better-ranked stock in the Medical – Products industry is Quidel Corporation QDEL, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Quidel Corporation (QDEL) : Free Stock Analysis Report
Rockwell Medical, Inc. (RMTI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
